A. Chalmers

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.

M. Drayson, J. Snowden, J. Cavenagh, 2014, The Lancet. Oncology.

Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

K. Boucher, W. Akerley, M. Esplin, 2019, Targeted Oncology.

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

J. Shammo, A. Chalmers, 2016, Therapeutics and clinical risk management.

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.

W. Akerley, Leif E. Jensen, A. Chalmers, 2017, Lung cancer.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.

J. Snowden, J. Cavenagh, G. Cook, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell harvesting after bortezomib-based re-induction for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF Myeloma X (Intensive) trial.

J. Snowden, J. Cavenagh, G. Cook, 2016 .

Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant.

S. Gregory, I. Miller, A. Chalmers, 2013, Clinical advances in hematology & oncology : H&O.

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

W. Gregory, A. Schuh, A. Duncombe, 2013 .

Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.

W. Akerley, A. Chalmers, L. Cannon, 2019, The oncologist.

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

J. Blay, G. Demetri, Melissa L. Johnson, 2021 .

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

W. Gregory, K. Brock, A. Rawstron, 2016 .

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuate

W. Gregory, R. Longo, J. O’Dwyer, 2017, Health technology assessment.